Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 30,833 shares of the medical research company’s stock after selling 335 shares during the period. Hancock Whitney Corp’s holdings in Edwards Lifesciences were worth $2,848,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth about $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $29,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $34,000. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Finally, Webster Bank N. A. purchased a new stake in Edwards Lifesciences in the second quarter valued at approximately $39,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.6 %

EW stock opened at $66.83 on Friday. The business’s 50-day moving average is $69.89 and its 200 day moving average is $82.83. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market cap of $40.27 billion, a price-to-earnings ratio of 28.81, a PEG ratio of 2.85 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.66 earnings per share. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of several research reports. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Wells Fargo & Company lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Stifel Nicolaus cut their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. UBS Group decreased their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $79.82.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,218,138 over the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.